Remedy Plan is a pre-clinical cancer therapeutics company developing first-in-class small molecule drugs that differentiate cancer cells.
Business Model:
Revenue: $0
Employees: 1-10
Address:
City: Gaithersburg
State: Maryland
Zip:
Country: United States
Remedy Plan Therapeutics is a pre-clinical-stage company developing small molecule therapeutics to halt tumor growth and disrupt the cancer stem cells that cause metastasis. Our approach is to develop effective, non-toxic treatments that target the dangerous embryonic properties of cancer stem cells, which form the basis for cancer growth, spread, and resistance to chemotherapy. Remedy Plan is positioned to deliver one first-in-class drug candidate for Phase I clinical development approximately 15 months after Series A funding Remedy Plan&s;s proprietary drug screening platform identifies drug candidates that differentiate cancer stem cells, disrupt proliferation, and inhibit formation of new tumors. From the initial screen of 40,000 drug components, a lead candidate is currently undergoing optimization and mechanism of action studies in preparation for Phase I clinical trials. With the second screen of over 100,000 drug components completed, Remedy Plan aims to have at least two drugs in clinical development by 2020.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 12/2019 | Venture Round | $5.2M | 10/2015 | Pre Seed Round | $100k | 10/2017 | Seed Round | $2.1M | 11/2018 | Venture Round | 1 | $1.5M |
Schooner Capital Schooner Capital |
1/2016 | Seed Round | $1.2M |
---|
Announced Date | Name | Price |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|